Patents Assigned to GENEVA UNIVERSITY HOSPITALS
  • ADAPTER MOLECULES TO RE-DIRECT CAR T CELLS TO AN ANTIGEN OF INTEREST
    Publication number: 20230242643
    Abstract: Chimeric antigen receptor (CAR) bridging protein are provided comprising a CAR-binding domain linked to an antigen-binding domain, which can be used to re-direct the targeting of CAR-T cells. The bridging protein may comprie an antigen-binding domain that targets any antigen of interest, such as, for example, a tumor antigen or viral antigen. Also provided are methods of using the bridging proteins in combination with CAR-T cells to treat a disease, such as, for example, a cancer or an infectious disease.
    Type: Application
    Filed: May 27, 2021
    Publication date: August 3, 2023
    Applicants: ANTION BIOSCIENCES SA, GENEVA UNIVERSITY HOSPITALS, UNIVERSITY OF GENEVA, UNIVERSITY OF ZURICH
    Inventors: Marco ALESSANDRINI, Karl-Heinz KRAUSE, Renier MYBURGH
  • Barbituric acid derivatives, their preparation and use thereof as leukocyte transmigration inhibitors and for treating inflammatory diseases, autoimmune diseases and cancer
    Patent number: 11492333
    Abstract: Provided herein are novel barbituric acid derivatives, their synthesis and use thereof in blocking leukocyte transmigration. The novel barbituric acid derivatives are useful for the treatment of disorders associated with leukocyte transmigration, such as for example inflammatory diseases and disorders, autoimmune diseases and disorders, and cancers.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: November 8, 2022
    Assignees: BAR-ILAN UNIVERSITY, UNIVERSITY OF GENEVA, GENEVA UNIVERSITY HOSPITALS
    Inventors: Arie Lev Gruzman, Paul Bradfield, Tamar Getter, Beat Imhof, Thomas Matthes, Hanoch Senderowitz